Drugs Archives - Page 25 of 65 - �鶹Ů�� Health News

KHN’s ‘What the Health?’: How to Expand Health Coverage

Democrats in Congress and the states are devising strategies to expand health coverage — through the Affordable Care Act, Medicare, Medicaid and a “public option.” But progress remains halting, at best. Meanwhile, lawmakers in Washington may have to agree on how to control prescription drug prices if they wish to finance their coverage initiatives. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Shefali Luthra of The 19th join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Michelle Andrews, who reported and wrote last month’s KHN-NPR “Bill of the Month” episode about a very expensive sleep study.

June 24, 2021

COVID-19

Is Rand Paul Mixing Up the Vaccine Message for Covid Survivors?

The scientific literature shows that natural immunity does provide protection against covid-19, but experts say getting vaccinated can provide additional protection against variants.

By Victoria Knight

June 22, 2021

The Spinal Tap

Device Makers Have Funneled Billions to Orthopedic Surgeons Who Use Their Products

Federal officials say that some of the money changing hands has corrupted doctors and endangered patients.

By Fred Schulte and Elizabeth Lucas

June 17, 2021

Podcast

KHN’s ‘What the Health?’: Our 200th Episode!

The federal approval of a controversial drug to treat Alzheimer’s disease has reignited the debate over drug prices and the way the Food and Drug Administration makes decisions. Meanwhile, President Joe Biden seeks to gain goodwill overseas as he announces the U.S. will provide 500 million doses of covid vaccine to international health efforts. Sarah Karlin-Smith of the Pink Sheet, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Chiquita Brooks-LaSure, the new administrator of the Centers for Medicare & Medicaid Services. And to mark the podcast’s 200th episode, the panelists discuss what has surprised them most and least over the past four years.

June 10, 2021

Change to Gilead Assistance Program Threatens PrEP Access, HIV Advocates Say

Safety-net clinics especially are bracing for how the drugmaker’s policy shift could reduce their budgets and hamstring their ability to provide care to an at-risk population.

By Carmen Heredia Rodriguez

June 10, 2021

COVID-19

Unused Johnson & Johnson Covid Doses Are Piling Up as FDA Waits to See if Shelf Life Can Be Extended

As vaccine expiration dates loom, states with hundreds of thousands of doses on hand say demand is tanking and there’s no easy way to donate to other states or countries that might want them

By Rachana Pradhan and Christina Jewett

June 8, 2021

FDA Weighs Approval of a Lucrative Alzheimer’s Drug, but Benefits Are Iffy

The agency is to decide by June 7 whether to greenlight Biogen’s drug aducanumab, despite a near-unanimous rejection of the product by an FDA advisory committee of outside experts in November. Some scientists at the agency have endorsed the drug, though.

By Harris Meyer

June 4, 2021

Podcast

KHN’s ‘What the Health?’: The Drug Price Dilemma

Republicans, Democrats and the public at large agree that prices for prescription drugs are too high. But no one seems to know how to fix it. Vanderbilt University drug price researcher Stacie Dusetzina explains the basics of why drugs cost so much and why it’s hard to do something about it. Joanne Kenen of Politico, Sarah Karlin-Smith of the Pink Sheet and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss the prospects for policy changes.

June 3, 2021

KHN On Air

KHN Journalist Combs for Clues on Covid’s Origins

KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.

May 29, 2021

Biden Administration Signals It’s in No Rush to Allow Canadian Drug Imports

Federal officials asked a court to dismiss a suit by drugmakers over the policy enacted by the Trump administration that would allow states to bring in cheaper prescription medications from Canada. The filing said the lawsuit was moot because it’s unclear when or if the FDA would approve any state’s importation plan.

By Phil Galewitz

May 28, 2021

Opioids Like ‘Lean’ Permeate Hip-Hop Culture, but Dangers Are Downplayed

In big cities and small towns, opioid use among some young hip-hop fans is about emulating their favorite rap star’s image — while paying little attention to the serious consequences.

By Chaseedaw Giles

May 28, 2021

Podcast

KHN’s ‘What the Health?’: The Return of the Public Option

Lawmakers are working on fleshing out the concept of a “public option,” a government-run or heavily regulated insurance plan that would compete with private insurance. But the details are complicated, both substantively and politically. Meanwhile, bioethicists are debating whether the U.S. should be vaccinating low-risk adolescents against covid-19 while high-risk adults in other countries are still waiting. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Rachana Pradhan of KHN join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

May 27, 2021

Colorado Lawmakers Wage Multifront Assault on High Drug Costs

Colorado is one of many states resolved not to wait for federal action to reduce drug costs. Its legislature is considering several ways to lower costs for consumers and the state.

By Markian Hawryluk

May 25, 2021

KHN On Air

KHN Journalists Comment on Abortion Case, Wasted Covid Doses

KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.

May 22, 2021

Podcast

KHN’s ‘What the Health?’: Drug Price Effort Hits a Snag

Democratic leaders in Congress have vowed to pass legislation to address high prescription drug prices this year, but some moderates in their own party appear to be balking. Meanwhile, younger teens are now eligible for a covid-19 vaccine and the Biden administration reinstated anti-discrimination policy for LGBTQ people in health care. Joanne Kenen of Politico, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.

May 13, 2021

KHN On Air

From Covid Coverage to ‘Public Option’ Plans, Journalists Delve Into Details

KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.

May 8, 2021

This Small Canadian Drugmaker Wants to Make J&J Vaccines for Poor Nations. It Needs More Than a Patent Waiver.

All agree that covid vaccines are urgently needed to stop the pandemic, but simply waiving patents fails to provide technological know-how and address supply chain challenges.

By Sarah Jane Tribble and Arthur Allen

May 6, 2021

Podcast

KHN’s ‘What the Health?’: Sharing Vaccines With the World

The Biden administration is bucking the drug industry and backing a waiver of covid-19 vaccine patent protections to help the rest of the world vaccinate its populations. Here at home, the Food and Drug Administration wants to ban menthol flavorings for cigarettes, setting off a fight with the tobacco industry. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Kimberly Leonard of Business Insider join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

May 6, 2021

The Last Drugstore

Covid Shot in the Arm Not Enough to Keep Pharmacies in Business

Pandemic lockdowns exacerbated long-standing economic pressures on pharmacies — and forced many owner-operated shops to evolve or risk closing their doors.

By Markian Hawryluk

May 5, 2021

HealthBent

Democrats Disagree About How to Spend Potential Prescription Drug Windfall

After a year of uncharacteristically being on the same page when it comes to health care, Democratic lawmakers are at loggerheads about what to do next. Most agree the time is ripe to tackle high drug prices. But they divide over whether to take savings from that to move to a ‘Medicare for All’ insurance system, enhance the current Medicare program or strengthen benefits under the Affordable Care Act.

By Julie Rovner

May 4, 2021

�鶹Ů��

Trump 2.0

Public Health

Audio Reports

Special Reports

More Topics

Drugs